Efficacy of Upadacitinib in Managing Coexisting Psoriasis and Lichen Planus: A Case Study

• by Xingmo Li, Jinxu Qi, Liping Shi, Lijuan Liu, Xiaoyu Xie, Guoqiang Zhang, Qing Zhu

• April 20, 2026

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

• by Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Angelo Valerio Marzano, Matteo Megna, Diego Orsini, Lidia Sacchelli, Santo Raffaele Mercuri, Emanuele Trovato, Serena Giacalone, Alexia Pedron, Marzia Caproni, Edoardo Cammarata, Aldo Cuccia, Andrea Altomare, Alexandra M. G. Brunasso, Valentina Dini, Simone Ribero, Nicola Zerbinati, Francesco Messina, Stefano Caccavale, Carlo G. Carrera, Luca Potestio, Viviana Lora, Andrea Carugno, Federico Bardazzi, Giovanni Paolino, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

• March 16, 2026

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

• by Kathryn Wighton

• May 18, 2026

• 2 min

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

• by Kerri Miller

• April 16, 2026

• 3 min